Pair page
Cartalax with GHK-Cu
Mechanism-tag overlap and published literature for Cartalax and GHK-Cu, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
khavinson-cartilage-bioregulator
connective-tissuecopper-tripeptide-skin
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Cartalax and GHK-Cu have published these mechanism-level observations. Not a co-administration recommendation.
GHK-Cu has broader connective-tissue regeneration data, including cartilage-associated ECM synthesis in preclinical models. Mechanistically complementary framing with Cartalax within connective-tissue protocols.
Quick facts
Cartalax
GHK-Cu
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2021 | Cartalax | Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID: 34834147. PMID 34834147 | systematic review |
| 2006 | Cartalax | Gumen AV, Kozinets IA, Shanin SN, Malinin VV, Rybakina EG. Production of lymphocyte-activating factors by mouse macrophages during aging and under the effect of short peptides. Bulletin of Experimental Biology and Medicine. 2006;142(3):360-362. PMID: 17266159. PMID 17266159 | preclinical, in vivo |
| 2016 | Cartalax | Linkova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, Khavinson VKh. Peptide regulation of skin fibroblast functions during their aging in vitro. Bulletin of Experimental Biology and Medicine. 2016;161(1):175-178. PMID: 27259486. PMID 27259486 | preclinical, in vitro |
| 2014 | Cartalax | Khavinson VKh, Tarnovskaya SI, Lin'kova NS, Polyakova VO, Durnova AO, Nichik TE, Kvetnoi IM, D'yakonov MM, Yakutseni PP. Short cell-penetrating peptides regulate fibroblast functions in cell cultures of young and old patients. Advances in Gerontology. 2014;27(4):651-656. (Key Ca… | preclinical, in vitro |
| 2011 | Cartalax | Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and the specific interaction of the peptides with deoxyribooligonucleotides and DNA in vitro. Biochemistry (Moscow). 2011;76(11):1210-1219. PM… PMID 22117548 | preclinical, in vitro |
| 2012 | Cartalax | Khavinson VKh, Solov'ev AIu, Zhilinskii DV. Molecular mechanism of the peptide regulation of gene expression: a review. Advances in Gerontology. 2012;25(3):447-456. PMID: 23289233. PMID 23289233 | mechanism / discovery |
| 2020 | Cartalax | Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide Regulation of Cell Differentiation. Stem Cell Reviews and Reports. 2020;16(1):118-125. PMID: 31813120. PMID 31813120 | bioregulator literature |
| 2016 | Cartalax | Vanyushin BF, Khavinson VKh. Short Biologically Active Peptides as Epigenetic Modulators of Gene Activity. In: Epigenetics — A Different Way of Looking at Genetics. Springer, 2016. DOI: 10.1007/978-3-319-27186-6_5. | bioregulator literature |
| 2012 | Cartalax | Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine. 2012;153(1):148-151. PMID: 22808513. PMID 22808513 | bioregulator literature |
| 2010 | Cartalax | Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19633997. PMID 19633997 | bioregulator literature |
| 2005 | Cartalax | Khavinson VKh, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger Publishers, Basel, 2005. ISBN 3-8055-7903-3. | bioregulator literature |
| 2002 | Cartalax | Khavinson VKh. Peptides and ageing. Neuroendocrinology Letters. 2002;23(Suppl 3):11-144. PMID: 12496732. PMID 12496732 | bioregulator literature |
| 1995 | GHK-Cu | Buffoni F, Pino R, Dal Pozzo A. Effect of tripeptide-copper complexes on the process of healing of cutaneous wounds in mice. Arch Int Pharmacodyn Ther. 1995;330(3):345-360. PMID: 9060874. PMID 9060874 | preclinical, in vivo |
| 1993 | GHK-Cu | Maquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, Trachy RE, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-2376. PMID: 8227353. PMID 8227353 | preclinical, in vivo |
| 2011 | GHK-Cu | Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res. 2011;60(1):79-86. PMID: 20835751. PMID 20835751 | preclinical, in vitro |
| 2007 | GHK-Cu | Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839. PMID: 17702486. PMID 17702486 | preclinical, in vitro |
| 1988 | GHK-Cu | Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Lett. 1988;238(2):343-346. PMID: 3169264. PMID 3169264 | preclinical, in vitro |
| 2017 | GHK-Cu | Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sci. 2017;7(2):20. PMID: 28212278. PMID 28212278 | mechanism / discovery |
| 2012 | GHK-Cu | Campbell JD, McDonough JE, Zeskind JE, Hackett TL, Pechkovsky DV, Brandsma CA, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med. 2012;4(8):67. PMID: 22937864. PMID 22937864 | mechanism / discovery |
| 1973 | GHK-Cu | Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-87. PMID: 4351857. (Original discovery publication.) PMID 4351857 | mechanism / discovery |
| 2026 | GHK-Cu | WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. | regulatory / registry |
| 2025 | GHK-Cu | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025-2026. | regulatory / registry |
| 2018 | GHK-Cu | Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520. doi:10.3390/ijms19071987. (Comprehensive modern review.) PMID 29986520 | research article |
| 2015 | GHK-Cu | Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. PMID: 26236730. PMID 26236730 | research article |
Related pair pages
More research context
Frequently asked
Have Cartalax and GHK-Cu been studied together?
Researchers have published mechanistic-level co-administration discussion of Cartalax and GHK-Cu. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Cartalax and GHK-Cu share?
Cartalax and GHK-Cu do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Cartalax and GHK-Cu?
Cartalax: Not approved. GHK-Cu: Cosmetic ingredient; Category 2 for injection. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Cartalax and GHK-Cu?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Cartalax profile and the GHK-Cu profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026